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In the actinorhodin type II polyketide synthase, the
first polyketide modification is a regiospecific C9-
carbonyl reduction, catalyzed by the ketoreductase
(actKR). Our previous studies identified the actKR
94-PGG-96 motif as a determinant of stereospeci-
ficity. The molecular basis for reduction regiospeci-
ficity is, however, not well understood. In this study,
we examined the activities of 20 actKR mutants
through a combination of kinetic studies, PKS
reconstitution, and structural analyses. Residues
have been identified that are necessary for substrate
interaction, and these observations have suggested
a structural model for this reaction. Polyketides
dock at the KR surface and are steered into the
enzyme pocket where C7–C12 cyclization is medi-
ated by the KR before C9-ketoreduction can occur.
These molecular features can potentially serve as
engineering targets for the biosynthesis of novel,
reduced polyketides.INTRODUCTION
Polyketide natural products are a large, diverse class of second-
ary metabolites with important biological activities (Crawford
and Townsend, 2010; Zhan, 2009). Many pharmaceutical
compounds are polyketide-based, including antibiotics (tetracy-
cline), anticancer agents (daunorubicin), and immunosuppres-
sants (FK506; Cane et al., 1998). Polyketide biosynthesis is
driven by the polyketide synthase (PKS), which is genetically
and functionally similar to fatty acid synthase (Hopwood,
1997). PKSs are generally divided into three classes (Shen,
2003), although the focus of this study is type II PKSs found in
bacteria, which biosynthesize aromatic polyketides, such as
actinorhodin (Malpartida and Hopwood, 1984). In the actinorho-
din (act) type II PKS (Figure 1), a linear poly-b-keto chain is
biosynthesized by the minimal PKS, consisting of the dimeric
ketosynthase-chain length factor (KS-CLF) and an acyl carrier
protein (ACP; Malpartida and Hopwood, 1984). Biosynthesis isChemistry & Biology 20, 1225–1initiated by an acetate starter unit derived from CLF-mediated
decarboxylation of a malonyl-ACP thioester. Subsequent chain
elongation occurs through decarboxylative condensation of
malonyl-based units to this starter, producing the final octake-
tide (16-carbon) intermediate (Das and Khosla, 2009). The first
modification of the nascent polyketide chain is catalyzed by
the actKR, which regiospecifically reduces a single carbonyl
group (typically at C9) to a hydroxyl group. This modification is
thought to occur after cyclization between C7 and C12 occurs,
which forms the first ring, a process that may also be directed
by the ketoreductase (McDaniel et al., 1993). Heterologous
expression and in vitro reconstitution experiments have demon-
strated that, in the absence of modifying enzymes, the act
minimal PKS produces both the correctly C7–C12 cyclized
SEK4 as well as the aberrantly C10–C15 cyclized SEK4b.
When actKR is present, however, the dominant product
becomes mutactin (C7–C12 cyclized), further suggesting that
correct cyclization is dependent on reductase activity (Khosla
et al., 1993; McDaniel et al., 1994; Zawada and Khosla, 1999).
Type II ketoreductases can potentially be utilized in organic
synthesis applications and in engineered biosynthesis (Broussy
et al., 2009; Grau et al., 2007; Jacobsen et al., 1998; Truppo
et al., 2007). This would require an in-depth understanding of
KR-substrate interactions, including the factors that dictate re-
gio- and stereospecificity. Our previous structural and biochem-
ical analyses led to the identification of the actKR 94-PGG-96
motif as a determinant of stereospecificity as well as residues
that interact with the inhibitor emodin (Javidpour et al., 2011;
Korman et al., 2008). Furthermore, docking studies suggested
a region on the actKR surface that could act as the site of inter-
action between KR and ACP (Javidpour et al., 2011). To fully
realize the potential of KR for engineered reduction, a detailed
assessment of the molecular basis for C9-regiospecificity and
the possible role of actKR in first-ring cyclization is required.
The aim of this work is to identify actKR residues that mediate
interactions with the natural polyketide substrate, the NADPH
cofactor and the carrier protein, as well as residues that direct
C9-regiospecific ketoreduction. We present the molecular
features of actKR involved in recognizing and directing the poly-
ketide intermediate for C9-ketoreduction. This is supported by
kinetic and in vitro PKS reconstitution assay data for 20 actKR
mutants. High-resolution crystallographic structures for three
of the mutants are also presented. We targeted specific actKR234, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1225
Figure 1. Schematic of the Actinorhodin Type II PKS
The minimal PKS synthesizes a 16-carbon polyketide intermediate that, in the absence of KR, spontaneously forms unreduced products SEK4 1 (C7–C12 first-
ring cyclization) and SEK4b 2 (C10–C15 first-ring cyclization). KR regiospecifically reduces C9, yielding a C7–C12 cyclized polyketide that formsmutactin 3 as the
major product. That all downstream products, including SEK34 5, DMAC 6, and actinorhodin 7, are C7–C12 cyclized suggests that KR also plays a role in the
determination of cyclization specificity.
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biochemical analyses of wild-type (WT) and P94L actKR, both
in the presence or absence of the inhibitor emodin (Javidpour
et al., 2011; Korman et al., 2004, 2008). These mutations can
be subdivided into three groups associated with surface, sub-
strate binding pocket, and the a6-a7 loop. Significantly, we
have shown that a single mutation in the actKR substrate pocket
can switch the stereospecificity between S-dominant and
R-dominant, which contradicts the results of type I polyketide
KR mutations (Baerga-Ortiz et al., 2006; Castonguay et al.,
2008; Holzbaur et al., 1999, 2001; Keatinge-Clay, 2007; Kea-
tinge-Clay and Stroud, 2006; O’Hare et al., 2006; Østergaard
et al., 2002; Siskos et al., 2005). These results form the basis
for a model of KR-mediated C7–C12 first-ring cyclization that
occurs within the enzyme binding pocket prior to ketoreduction.
RESULTS
Overall Strategy
Based on previous structural and biochemical analyses of
wild-type and P94L actKR (Javidpour et al., 2011; Korman
et al., 2004, 2008), we proposed three groups of mutations:
surface mutations to evaluate protein-protein interactions and1226 Chemistry & Biology 20, 1225–1234, October 24, 2013 ª2013 Elong-range effects on enzyme activity, substrate binding pocket
mutations to assess stereospecificity and catalytic efficiency,
and finally mutations in the a6-a7 loop to determine if this flexible
region plays a significant role in catalysis. Trans-1-decalone and
tetralol were used as substrate analogs to kinetically assay
catalytic efficiency and substrate specificity of the reduction
(Tables 1 and 2; Table S1 available online). Trans-1-decalone,
which has previously been used as a model substrate to assay
ketoreductase activity in both fatty acid synthase and PKS
(Dutler et al., 1971; Østergaard et al., 2002), was shown to be a
more effective substrate for the actKR than 1-tetralone (Korman
et al., 2008).
Extensive studies of type I polyketide KRs have shown that
their mutation often results in a mixture of enantiomeric reduced
products and that multiple residues, located both within and
distal to the active site, determine the stereospecificities of
type I KRs (Baerga-Ortiz et al., 2006; Castonguay et al., 2008;
Holzbaur et al., 1999, 2001; Keatinge-Clay, 2007; Keatinge-
Clay and Stroud, 2006; O’Hare et al., 2006; Østergaard et al.,
2002; Siskos et al., 2005). In contrast, our previous studies of
the type II polyketide KRs have shown that whereas wild-
type actKR displays a 3:1 preference for S- over R-stereochem-
istry based on catalytic specificities for oxidation of tetralollsevier Ltd All rights reserved
Table 1. Kinetic Parameters for the Reduction of trans-1-Decalone and interaction with NADPH and ACP byWild-Type andMutants of
Actinorhodin Ketoreductase
kcat (s
1) Km (mM) kcat/Km (s
1 mM1) KD (mM) NADPH KD (mM) ACP
WT 2.55 ± 0.12 0.76 ± 0.09 3.23 ± 0.32 – –
D109E 1.17 ± 0.12 0.71 ± 0.18 1.64 ± 0.45 – –
D109R 0.078 ± 0.01 1.25 ± 0.40 0.062 ± 0.021 – –
S144C inactive – –
T145A 0.18 ± 0.008 0.42 ± 0.06 0.42 ± 0.06 – –
G146V inactive – –
V151A inactive – –
V151L 1.24 ± 0.07 0.97 ± 0.12 1.28 ± 0.18 – –
A154G 1.33 ± 0.16 0.50 ± 0.18 2.68 ± 1.03 – –
F189A 0.049 ± 0.005 8.63 ± 2.01 0.0057 ± 0.0015 – –
F189W substrate inhibition – –
M194W 0.43 ± 0.06 3.22 ± 0.65 0.13 ± 0.03 – –
V198A 0.24 ± 0.01 15.50 ± 1.49 0.016 ± 0.002 – –
V198Ga 1.3 ± 0.1 0.32 ± 0.06 5.36 ± 1.12 0.060 ± 0.017 – –
Y202Aa 2.0 ± 0.3 1.80 ± 0.09 1.07 ± 0.09 1.69 ± 0.16 – –
Y202F 2.01 ± 0.17 0.40 ± 0.11 5.01 ± 1.44 – –
WTb 2.00 ± 0.06 1.19 ± 0.02 1.68 ± 0.08 1.52 ± 0.09 0.20 ± 0.08
R38A 0.16 ± 0.03 1.45 ± 0.02 0.11 ± 0.02 4.30 ± 0.40 1.52 ± 0.12
R65A 1.97 ± 0.07 1.24 ± 0.02 1.59 ± 0.07 1.83 ± 0.21 0.53 ± 0.11
R93A 1.13 ± 0.05 1.21 ± 0.01 0.94 ± 0.05 6.43 ± 0.68 0.53 ± 0.07
R177A 1.99 ± 0.03 1.26 ± 0.01 1.58 ± 0.03 1.17 ± 0.10 0.49 ± 0.12
R220A 1.78 ± 0.06 1.18 ± 0.02 1.51 ± 0.06 1.99 ± 0.16 0.61 ± 0.10
aKinetic parameters determined using the Hill equation: v = (Vmax 3 [S]
n)/(K0 + [S]n). The Hill coefficient (n) is listed under the mutation identifier.
bKinetic parameters determined independently. The relative rate parameters for the argininemutations below should be compared to this value forWT.
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stereospecificity of actKR to S-dominant, with no detectable
activity toward R-tetralol (Javidpour et al., 2011). The term
S-dominant herein is used to describe actKR mutants that
display higher preference for S- over R-tetralol as compared to
the wild-type enzyme. Our previous results also implied that
long-ranged effects might be important for stereospecificity.
We therefore constructed binding pocket mutants to determine
how these residues affect KR stereospecificity. ActKR mutants
were also assayed through in vitro reconstitution of the extended
minimal PKS (act min PKS plus actKR). With the exception of
evaluation of surface arginine mutants where actACP was used
for an accurate ACP-KR binding measurement, actACP was
substituted with the orthologous frenN ACP for all reconstitution
assays. The frenN ACP can be expressed at higher levels than
the actinorhodin carrier protein and forms a stable protein com-
plex (Khosla et al., 1993). Products from mutant KR reconstitu-
tion experiments were compared to those from both the act
min PKS or the extended minimal complex. Activity, relative to
that of wild-type actKR, was assessed by comparing the ratio
of the area of the mutactin peak to the average of both SEK4
and SEK4b peaks.
Surface Residue Mutants Display Greatly Diminished
Activity and KR-ACP Interactions
Surface residues were mutated to assess whether R38A, R65A,
R93A, and D109E/R of actKR form a patch that interacts withChemistry & Biology 20, 1225–1ACP (Figure 2A). Previous in silico docking and mutational
analyses suggested that the arginine residues, along with
D109, form a charged groove that promotes complementary
interactions with both helix II and the phosphopantetheine
(PPant) group of the ACP (Korman et al., 2008; Tang et al.,
2006). The D109 b-carboxyl group is within hydrogen-bonding
distance of both the R65 and R93 side chains. This interaction
may maintain the structure of the phosphate-binding groove.
PKS reconstitution analysis showed that mutants R65A and
R93A produced less mutactin than wild-type actKR, based on
the respective mutactin:SEK4(b) ratios, while reconstitution
with R38A actKR led to no detectable level of mutactin (Figure 3).
To determine the dissociation constants (Kd) between actACP
and actKR, separate fluorescence binding assays were
measured (Figure S3). Here, the R38A actKR mutant displayed
the weakest interaction (Kd 1.52 mM versus 0.20 mM for wild-
type). Mutants R65A and R93A both displayed a Kd value of
0.53 mM. The D109E actKRmutation had little effect on mutactin
production (Figure 3), catalytic turnover in the trans-1-decalone
assay, or activity when assayed with S- and R-tetralol (Table 1).
The D109R mutant, in comparison, shows a 30-fold reduction in
trans-1-decalone turnover and is inactive when assayed with S-
and R-tetralol (Tables 2 and S1). The conservative D109E muta-
tion is therefore, tolerated, while D109R strongly influences
catalysis and may destabilize the adjacent arginine patch.
NADPH binding to both wild-type actKR and the three arginine
mutants (R38A, R65A, and R93A) was also determined using a234, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1227
Table 2. Oxidation of S-(+)-Tetralol and R-(–)-Tetralol by Wild-
Type and Mutants of Actinorhodin Ketoreductase
General
Mutation
Location
S-(+)-Tetralol
kcat/Km
a
R-()-Tetralol
kcat/Km
a
S:R Activity
Ratiobs1mM1 % s1mM1 %
WT – 0.035 100 0.010 100 3.5
D109E surface 0.0063 18 0.0012 12 5.3
D109R surface inactive
S144C pocket inactive
T145A pocket .0041 12 inactive NA
G146V pocket inactive
V151A pocket inactive
V151L pocket substrate
inhibition
0.026 260 NA
A154G pocket 0.018 51 0.0021 21 8.6
F189A pocket 0.0070 20 inactive NA
F189W pocket 0.029 83 0.0026 26 11.2
M194W pocket 0.034 97 inactive NA
V198A pocket 0.023 66 0.020 200 1.2
V198G pocket 0.0012 3 0.00083 8 1.5
Y202A a6-a7 loop 0.039 111 0.0078 22 5.0
Y202F a6-a7 loop 0.016 46 0.0048 14 3.3
See also Tables S1, S3, and S4 and Figure S1.
aCatalytic specificity (kcat/Km) expressed as percentage of wild-type
value.
bRatio of S-tetralol to R-tetralol kcat/Km values.
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was obtained, a value similar to that previously determined
(5 mM; Korman et al., 2008). The R38A and R93A actKR mutants
showed approximately 3-fold and 8-fold reductions in NADPH
binding, respectively, while R65A was unchanged. These results
suggest that residues R38, R65, R93, and D109 are important for
KR-ACP binding and activity. Mutations targeting the surface
residues lead to disruption of the KR-ACP interaction and
decreased activity toward the PPant-tethered polyketide
substrates.
KR Pocket Mutants: Nonpolar Side Chains Are
Necessary for Substrate Interactions
The amphipathic nature of the polyketide intermediate requires
both hydrophilic and hydrophobic residues for substrate
binding and the prevention of premature polyketide cyclization
(Keatinge-Clay et al., 2004). With this in mind, a number of
substrate binding residues were identified based on actKR-
emodin co-crystal structures (Korman et al., 2008). These
mutated residues include S144C, T145A, G146V, V151A/L,
A154G, F189A/W, M194W, and V198A/G (Figures 2B and 2C).
Mutants S144C and G146V were specifically designed to
assess their role in C9-oxyanion stabilization during polyketide
reduction. The S144C mutant was constructed to test substitu-
tion of the serine b-hydroxyl with a weaker hydrogen-bonding
functional group. Residue G146 is located behind catalytic
residues S144 and Y157. Mutation of this glycine to the larger,
non-polar valine residue is expected to sterically hinder polyke-
tide binding in the active site by disrupting the arrangement of1228 Chemistry & Biology 20, 1225–1234, October 24, 2013 ª2013 ES144 and Y157. As expected, mutants S144C and G146V did
not produce any detectable levels of mutactin (Figure 3). Both
mutations exhibited low activity toward S- and R-tetralol, and
were inactive when assayed with trans-1-decalone (Tables 1,
2, and S1).
V151 is crucial for substrate recognition. The V151A mutant
was inactive toward both trans-1-decalone and tetralol (Tables
1, 2, and S1). V151 is located 5 A˚ from Y157 near the base of
the monomer cleft (Figure 2B). The branched side chain of resi-
due 151 extends into the binding pocket where non-polar inter-
actions orient the substrate prior to reduction. In contrast, the
conservative V151L mutation displayed kcat and Km values for
trans-1-decalone and R-tetralol turnover that were comparable
to those of wild-type actKR, supporting the hypothesis that a
large hydrophobic side chain is required at this position to steer
substrate binding and sustain reductase activity. V151L did,
however, produce 20-fold less mutactin than wild-type actKR
(Figure 3). Here, the leucine side chain may interfere with polyke-
tide binding, further highlighting the requirement for precise
steric control within the active site. This may explain the high
sequence conservation of V151 among type II PKS KRs.
The value for kcat/Km of A154G actKR in the trans-1-decalone
assay was similar to that of the wild-type enzyme, while the
activity using both S- and R-tetralol substrates was also rela-
tively high compared to the other mutants (Tables 2 and S1).
F189 mutations (F189A and F189W), however, displayed the
lowest activity toward trans-1-decalone (Table 1). Activity of
both mutants was also significantly reduced where R-tetralol
was used as the substrate, though turnover of the S-enantiomer
by the F189W mutant enzyme approached wild-type levels. The
F189W mutant also produced much lower levels of mutactin
when compared to wild-type actKR, while mutactin production
in F189A was almost undetectable (Figure 3). Assay results for
the F189 mutants suggest that, similar to V151, residue F189 is
crucial for enzyme-substrate interaction.
MutationM194Wabolishedmutactin production, and reduced
trans-1-decalone turnover to 5% of wild-type. The actKR con-
taining this methionine-tryptophan mutation was completely
selective for the S-enantiomer of tetralol. Here the bulky trypto-
phan may sterically clash with the NADPH nicotinamide, residue
P94, or with polyketide binding.
The V198G mutation drastically reduces mutactin production
and shows markedly decreased activity toward both S- and
R-tetralol (Table 2). A V198A mutation in comparison only shows
moderate changes in these assays, with a small increase in
R-tetralol selectivity. Progressive reduction of the hydrophobic
side chain at this position clearly exerts strong effects on enzyme
activity and fidelity of polyketide chain processing.
Aromatic Interaction in the a6-a7 Loop Region May Be
Important for Substrate Recognition
The type II PKS KRs possess a distinctive 11-residue insertion in
the a6-a7 loop (actKR residues 199–209; Korman et al., 2008).
This loop is the least conserved region in the short-chain dehy-
drogenase/reductase (SDR) superfamily of proteins, to which
actKR belongs, and may contribute to SDR substrate specificity
(Oppermann et al., 2003). Residue Y202 is highly conserved
among the type II KRs (Figure S2A). Our previous studies
suggested that a6-a7 loop residues may play an important rolelsevier Ltd All rights reserved
Figure 2. ActKRResidues Targeted for Site-
Directed Mutagenesis
(A) Arginines 38, 65, and 93 (green) are proposed
to stabilize the PPT phosphate group during the
binding of polyketide intermediate (yellow ball and
sticks).
(B) Pocket residues (green) near catalytic S144 and
Y157 (magenta) that interact with cocrystallized
emodin (orange). NADPH (green ball and sticks)
and P94 (teal) are shown for perspective and the
location of G146 is highlighted in blue.
(C) Residues F189, M194, and V198 (green) rela-
tive to S144, Y157, and emodin.
See also Figure S2 and Table S2.
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We therefore constructedmutants Y202A and Y202F to evaluate
the respective contributions of an aromatic side chain and a
phenolic hydroxyl group toward substrate recognition and
activity.
The Y202 mutants displayed activities toward trans-1-deca-
lone and tetralol that are comparable to those of wild-type
(Tables 1, 2, and S1). However, mutactin production by the
Y202A mutant is reduced, suggesting that complete removal of
the aromatic side chain negatively influences substrate turnover.
Y202 may be involved in p-p interactions with W206 that stabi-
lize the a6-a7 loop conformation and might therefore play a
structural rather than a catalytic role. This may also explain
why aromatic pairs are highly conserved among type II PKS
KRs (Figure S2A) at these positions.
Two further residues, R177 that packs against the a6-a7 loop
from an adjacent KR subunit in the tetramer, and R220 that
packs against Y202, were both mutated to alanine (Tables 1, 2,
and S1; Figure 3). Neither mutation had a significant effect in
any of the activity assays, or NADPH or ACP binding.
Structural Analysis of V151L, F189W, and Y202F ActKR
Three of the mutants that displayed intriguing assay results were
crystallized, and their structures were solved: V151L (for its
R-tetralol specificity), F189W (for its S-tetralol specificity), and
Y202F (to probe the long-range effect of the a6-a7 loop). Overall,
the structures are very similar to the NADPH-bound structures of
wild-type and P94L actKR (Javidpour et al., 2011). The alignment
root-mean-square deviations (rmsd) of the mutant structures
relative to wild-type are: 0.41, 0.44, and 0.35 A˚ for V151L,
F189W, and Y202F, respectively, and 0.41, 0.55, and 0.40 A˚ rela-
tive to P94L. The alignments of the catalytic residues (N114,
S144, Y157, and K161) and the NADPH cofactor have similar
positions and conformations (Figure 4A). The threemutant struc-
tures show that while mutations significantly altered observed
activities and regio- and stereospecificities in three different
assays, the overall protein conformations are not changed.
Despite the high overall similarity, there are structural differ-
ences that distinguish the three mutants from the previously
characterized crystal structures (Korman et al., 2004, 2008).
Alignment of the B subunits shows that in the V151L, F189W,
and Y202F mutants, the a6-a7 loop adopts a more closed
conformation than the wild-type (Figures 4 and S2B). In these
mutants M194 becomes extended and is potentially involved in
nonpolar interactions with P94. When V151L is aligned to wild-Chemistry & Biology 20, 1225–1type actKR, L151 of subunit A extends into the substrate pocket
in a similar conformation to V151. In the mutated subunit B,
however, L151 points toward the a6-a7 loop, thus creating a
closed conformation and a smaller substrate pocket (Figure 4B).
Similarly, in F189W the tryptophan aromatic ring overlaps with
the wild-type residue F189, while L258 interacts with W189,
again resulting in a smaller substrate pocket in monomer A. In
the wild-type enzyme, the Y202 side chain potentially forms a
water-mediated hydrogen bond with the H153 backbone
carbonyl and consequently points away from the a6-a7 loop.
In the F202 mutant, however, the phenylalanine ring rotates
back into the substrate binding pocket, possibly due to loss of
this hydrogen bonding interaction (Figure 4D). The V151L,
F189W, and Y202F mutations therefore result in a smaller sub-
strate pocket for monomer B, which contributes to the observed
low mutant enzyme activities. The altered pocket shape also
imposes more steric hindrance in V151L, resulting in the
observed substrate inhibition (Tables 2 and S1).
Docking Analyses: The Molecular Basis for V151L and
F189W Tetralol Assay Results
Mutant V151L displayed unusual activity toward tetralol, with
almost threefold higher activity toward the R-stereoisomer than
that of wild-type (Tables 2 and S1).When assayedwithS-tetralol,
however, we observed substrate inhibition at high (>2 mM)
S-tetralol concentrations. Both tetralol stereoisomers were
docked within the V151L actKR substrate binding pocket using
the program GOLD (Verdonk et al., 2003). The docking results
yielded similar positions and conformations for each stere-
oisomer, whereas for the wild-type actKR structure, R-tetralol
does not consistently dock. In the V151L mutant, the R-tetralol
aromatic ring consistently docks within the opening of the sub-
strate binding cleft (Figure S1A), consistent with the high kcat/Km
of this mutant for R-tetralol relative to the wild-type enzyme. In
contrast, the simulations showed that S-tetralol docks with the
aromatic ring near residues T145, F189, and L258, which avoids
clashes with L151. S-tetralol may, therefore, be lodged between
these three residues, causing the enzyme to be ‘‘trapped’’ in a
substrate-bound state (ES) by the high affinity for S-tetralol
and resulting in the observed substrate inhibition phenomenon.
This phenomenon has not been reported for type I polyketide
KRs and demonstrates that the type II polyketide KR is distinct
in its ability to switch stereospecificity through a single mutation.
To ascertain the molecular basis for the high F189W
stereospecificity, S- and R-tetralol were again docked within234, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1229
Figure 3. High-Performance Liquid Chromatography of
Products from In Vitro PKS Reconstitution Assays
The traces are divided into four sections for clarified viewing, with
each section including the traces for minimal PKS alone and with
wild-type actKR as references. Products include SEK4 1, SEK4b 2,
and mutactin 3. For each active KR, the number to the right of a
trace denotes the respective mutactin:SEK4 + SEK4b ratio. The
general mutation locations are also listed to the right of the
sections.
See also Figure S3.
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specificity may arise from a combination of steric hindrance,
(as for P94L or M194W actKR), as well as from the W189 indole1230 Chemistry & Biology 20, 1225–1234, October 24, 2013 ª2013 Elsevier Ltdgroup, which may adopt a different rotamer conforma-
tion upon substrate-binding. This allows p-p interac-
tions with the S-tetralol benzyl moiety, but not with
the R-stereoisomer (Figure S1B). The adoption of a
different rotameric state is supported by the crystallo-
graphic data, wherein there is well-defined 2Fo-Fc elec-
tron map density for W189 in subunit A of the mutant,
but weaker density for the residue in subunit B. This
suggests the presence of multiple rotamers in subunit
B. The steric effect exerted by W189 thus steers the
mutant toward S-dominant stereospecificity.
DISCUSSION
Based on the results of kinetic and reconstitution
assays, structural analyses, docking simulations, and
incorporation of previous studies (Javidpour et al.,
2011; Korman et al., 2004, 2008), we propose the
following model for polyketide docking, entrance into
the substrate pocket, C7–C12 first-ring cyclization,
and stereospecific ketoreduction by a type II polyketide
KR that accounts for the observed properties of
wild-type and mutant actKR (Figure 5).
PPant-Tethered Polyketide Docking
Docking results described in this paper, combined with
studies of the homologous S. coelicolor SCO1815 KR
(Javidpour et al., 2011; Tang et al., 2006), identify an
arginine patch as the putative docking site of the PPant
phosphate (Figure 2A). In the tetrameric actKR struc-
ture, the arginine patch is accessible on eachmonomer
and is not hindered by any neighboring molecule. The
assay results for the R38A, R65A, and R93A mutants,
which displayed decreased reconstitution activity and
interaction with ACP, lend further support to the impor-
tance of the arginine patch for enzyme activity.
Access to the ActKR Substrate Pocket
The docked PPant carrying the polyketide intermediate
must now access the actKR active site. Two openings
are seen in the surface representation of wild-type
actKR subunit A, separated by P94 and the M194,
which hereafter are referred to as ‘‘gate’’ residues (Fig-
ure 5A). The importance of M194 is supported by as-says of the M194W mutant, which produced less mutactin
than expected based on the trans-1-decalone assay. Themutant
tryptophan may sterically hinder polyketide docking, or blockAll rights reserved
Figure 4. Mutant ActKR Structural Analysis
(A) (Left) Alignment of monomer B of V151L
(magenta), F189W (blue), and Y202F (yellow) to
that of wild-type actKR (green). Although the
catalytic residues and NADPH cofactors align well,
the mutant monomers are in a closed conforma-
tion relative to wild-type, as seen by the shifts in
the labeled a6-a7 loops and extended M194 side
chains (right).
(B) Residue 151 extends into the substrate pocket
similarly in monomer A of wild-type (green) and
V151L (magenta; left), but L151 in the mutant
monomer B points more toward the a6-a7 loop,
creating a smaller substrate pocket (right).
(C) The aromatic plane of W189 in the F189W
mutant (blue) coincides with that of wild-type F189
(green). L258 may hydrophobically interact with
W189, limiting the substrate pocket size.
(D) Residue 202 overlaps when monomer A of
wild-type (green) and Y202F (yellow) are aligned
(left), but in monomer B (right), the wild-type Y202
points away from the substrate pocket while the
mutant F202 points within the pocket.
See also Figure S2.
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the opening immediately proximal to the arginine patch is further
blocked by the NADPH pyrophosphate moiety. The polyketide
must, therefore, enter the pocket through the cleft below the
P94 and M194 gate residues.
Steering of Polyketide toward the Active Site and
Monomer Closing
The polyketide substrate must be directed by the ‘‘steering’’ res-
idues, which include the hydrophobic V151, F189, and V198.
These residues must be non-polar and not glycine as suggested
by the assay results for V198G, which produced less mutactin
than expected. The V198 side-chain protrudes into the enzyme
cleft, effectively steering the PPant arm and polyketide interme-
diate toward the active site residues (Figure 5B). V198 may also
participate in non-polar interactions with the end of the PPant
arm distal from ACP. Furthermore, the V151 and F189 side-
chains define the narrow cleft and limit substrate movement.
This is supported by assays of the V151 mutants: V151A is inac-
tive toward trans-1-decalone, whereas V151L is active and leads
to mutactin production, suggesting the need for a bulky residue
at this position. Similarly, the need for a bulky residue at position
189 is supported by assays of F189A and F189W. The latter
mutant produced more mutactin when compared to F189A,
despite the presence of the bulky tryptophan.
KR-Mediated C7-C12 First-Ring Cyclization and C9-
Ketoreduction
Having been steered toward the active site, the linear polyketide
is then positioned so that the C11-carbonyl can interact through
hydrogen-bonding with T145, which is highly conserved among
type II KRs. This interaction could sufficiently lower the pKa of the
C12 a-protons (Gerlt et al., 1991) so that a proton can be
abstracted by water in the substrate-binding pocket. This leads
to C7–C12 cyclization, with the C7-oxyanion stabilized by water-
mediated hydrogen bonding to the highly conserved S158. ThisChemistry & Biology 20, 1225–1mechanism is supported by assays of T145A, which displayed
activity toward trans-1-decalone (Table 1), but intriguingly did
not produce any detectable level of mutactin. Other mutants
less active toward trans-1-decalone than T145A were able to
produce some mutactin (Figure 3). We therefore propose that
T145 is involved in C7–C12 polyketide cyclization through
hydrogen bonding with the C11-carbonyl, which lowers the
pKa of the C12 protons via enolate stabilization.
The model presented in this paper helps to explain how the
actKR affects cyclization specificity such that all downstream
products of the PKS are cyclized between C7 and C12. In the
absence of KR, approximately equal amounts of SEK4 (C7–
C12 cyclized) and SEK4b (C10–C15 cyclized) are produced by
the minimal PKS (Figure 1). The KR may, therefore, serve as a
scaffold that steers the polyketide substrate toward T145 for
C7–C12 cyclization, which then forces the C9-carbonyl within
the active site for regiospecific ketoreduction (Figure 5C). If the
polyketide intermediate were not cyclized, the C9-carbonyl
would be able to adopt a number of orientations. In addition,
C7–C12 cyclization would restrict the mode of polyketide bind-
ing within the active site, which explains why actKRmay produce
only one enantiomer of mutactin in vivo (Javidpour et al., 2011).
The absence of hydrogen bond donation from T145A would pre-
vent directed cyclization from occurring, which in turn would
compromise ketoreduction. As a result, the ACP-bound polyke-
tide may pull out of the KR pocket and spontaneously cyclize in
solution to yield SEK4 and SEK4b.
We propose that during ketoreduction, actKR achieves a
closed-state when the a6-a7 loop moves toward the opposite
side of the enzyme cleft, with p-p interactions between the high-
ly conserved residues 202 and 206 maintaining the loop confor-
mation as it closes in on the polyketide substrate (Figure S2). This
motion effectively traps the polyketide within the enzyme, yet
leaves openings for water to enter the binding site. Themonomer
opens once catalysis is complete, allowing the ACP-bound
reduced polyketide to leave the enzyme. In this regard, the234, October 24, 2013 ª2013 Elsevier Ltd All rights reserved 1231
Figure 5. Stereo Images of Proposed Inter-
actions between Polyketide and Wild-Type
ActKR
The polyketide chain is represented in yellow and
actKR in transparent white surface.
(A) Ligand docking results suggest that after the
PPT phosphate binds within the arginine patch
groove (blue surface), the polyketide chain enters
the substrate pocket underneath the gate residues
P94 and M194 (green spheres) to access the
active site.
(B) The polyketide intermediate is steered toward
the active site by the bulky residues V151, F189,
and V198 (purple sticks), which presumably
constrain chain movement.
(C) Ligand docking also suggests that T145
(teal) may stabilize the C11-oxyanion after C12
deprotonation through hydrogen bonding, thus
lowering the C12-proton pKa and allowing C7–C12
cyclization to occur. S158 (teal) may stabilize the
resulting C7-oxyanion through water-mediated
hydrogen-bonding. Both T145 and S158 are highly
conserved among type II KRs.
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(Keatinge-Clay et al., 2004), where an amphipathic tunnel is
needed for polyketide elongation toward the KS-CLF gate resi-
dues (Tang et al., 2003). The situation is arguably more complex
for the actKR, however, as a tunnel would prevent KR frommedi-
ating cyclization. The actKR pocket must, therefore, be large
enough to accommodate a monocyclized polyketide, yet still
maintain tight interactions with the substrate so that release
does not occur before reduction. The bulky residues, V151,
F189, and V198, are necessary to both steer and cradle the
polyketide in position until catalysis is complete.
SIGNIFICANCE
Type II polyketides includemany antibiotics and chemother-
apeutic agents that are of interest to the pharmaceutical
industry (Saleem et al., 2010). The type II polyketide KR is
an important modification enzyme that introduces chemical
diversity in polyketides by reducing intermediates with high
regio- and stereospecificity and possibly mediating a
specific C7–C12 first-ring cyclization. Previous biochemical
and structural analyses have identified the ‘‘PGG’’ motif as
important for in vitro stereospecificity (Javidpour et al.,
2011; Korman et al., 2008). In this work, we depart from the
status quo to elucidate the roles of surface, binding pocket,
and loop-region residues of actKR through a suite of infor-
mative tools: site-directed mutagenesis, kinetic assays,
and PKS reconstitution assays. Highly consistent results
from three different assays of 20 mutants offer a rich array
of information about the type II KR, such as the identification
of bulky hydrophobic pocket residues that are necessary to
serve as ‘‘gate’’ and ‘‘steering’’ residues for substrate bind-1232 Chemistry & Biology 20, 1225–1234, October 24, 2013 ª2013 Elsevier Ltd All rights resing. We have also shown that a single
mutation (V151L) converts stereospec-
ificity to R-dominant, as opposed to
other single mutations that result inS-dominant stereospecificity. Furthermore, the T145mutant
provided experimental support to the suggestion that this
type II KR fosters first-ring cyclization between C7 and
C12. The results support a proposed model for polyketide
docking, entrance into the KR enzyme pocket, cyclization,
and ketoreduction that accounts for the high specificity of
actKR. The molecular features identified in this work will
serve as protein engineering targets for rational control of
KR specificity to produce new polyketides with pharmaceu-
tical potential.
EXPERIMENTAL PROCEDURES
ActKR, ActKS-CLF, Holo-FrenN ACP, and MAT Protein Expression
and Purification
Recombinant wild-type or mutant actKR, actKS-CLF, holo-ACP and MAT
proteins were express and purified as described previously (Korman et al.,
2004, 2008; Matharu et al., 1998; Li et al., 2003; (Kumar et al., 2003). Additional
details can be found in the Supplemental Experimental Procedures.
In Vitro trans-1-Decalone, Tetralol, and In Vitro PKS Reconstitution
Assays for ActKR Activity
Steady-state kinetic parameters for wild-type and mutant actKR were deter-
mined bymonitoring reduction of trans-1-decalone in the presence of NADPH,
by monitoring oxidation of S-(+)- or R-()-tetralol in the presence of NADP+,
and PKS reconstitution assay. Steady-state kinetic data are listed in Tables
1, 2, and S1. Additional details can be found in the Supplemental Experimental
Procedures.
In Vitro Tetralol Assay for ActKR Stereospecificity
Steady-state kinetic parameters for wild-type and mutant actKR were deter-
mined by monitoring oxidation of S-(+)- or R-()-tetralol in the presence of
NADP+. Summarized kinetic data are listed in Table 2 and detailed steady-
state data in Table S1. Additional details can be found in the Supplemental
Experimental Procedures.erved
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To gauge interaction between ACP and either wild-type, or mutant KR, actACP
was titrated into a solution of actKR containing 25 mMNADPH and 1 mM DTT.
Fluorescence emission spectra were collected over the range of 320–380 nm
at a 295-nm excitation wavelength (tryptophan fluorescence). For NADPH
binding, increasing concentrations of NADPH (0–38 mM) were titrated in
actACP (1 mM) and the NADPH fluorescence was excited at 340 nm and
monitored between 400 and 500 nm. Additional details can be found in the
Supplemental Experimental Procedures.
Protein Crystallization, Data Collection, and Structure Solution
Experimental procedures and statistics for structure determination of the
V151L, F189W, and Y202F actKR mutants can be found in the Supplemental
Experimental Procedures.
ACCESSION NUMBERS
The PDB accession numbers for the V151L, F189W, and Y202F actKR struc-
tures reported in this paper are 4DBZ, 4DC0, and 4DC1, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2013.07.016.
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